Literature DB >> 22248667

Thermosensitive eyedrops containing platelet lysate for the treatment of corneal ulcers.

Giuseppina Sandri1, Maria Cristina Bonferoni1, Silvia Rossi1, Franca Ferrari1, Michela Mori1, Claudia Del Fante2, Cesare Perotti2, Carla Caramella3.   

Abstract

Corneal lesions cause significant pain and visual impairment and, in many cases, are unresponsive to conventional treatments. Platelet lysate (PL) is an haemoderivative rich in growth factors (GFs) that are released by platelets after freeze-thawing destruction of platelet rich plasma (PRP). The aim of the present work was to develop thermosensitive and mucoadhesive eyedrops to maintain and prolong the contact of platelet lysate (PL) with cornea ulcers. A sterile vehicle based on chondroitin sulphate sodium (CS) and hydroxypropylmethyl cellulose (HPMC) was developed. An extemporaneous loading of the vehicle with PL was performed and the obtained formulation was able to quickly thermogelify at about 32 °C and was characterized by good mucoadhesive properties. ELISA evidenced that the growth factor PDGF AB was compatible with the vehicle and stable in the formulation up to 15 days of storage at 2-8 °C. In vitro wound healing and proliferation test (performed using rabbit corneal epithelial cells (RCE)) showed that the formulation enhanced cell growth and put in evidence a synergistic effect of CS and PL in stimulating cell proliferation. The overall results indicate that PL loaded in thermosensitive and mucoadhesive eyedrops can be profitably employed to treat corneal lesions.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22248667     DOI: 10.1016/j.ijpharm.2011.12.059

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  7 in total

Review 1.  Platelet-Rich Plasma Promotes Axon Regeneration, Wound Healing, and Pain Reduction: Fact or Fiction.

Authors:  Damien P Kuffler
Journal:  Mol Neurobiol       Date:  2015-06-06       Impact factor: 5.590

2.  Comparison of corneal epitheliotrophic capacities among human platelet lysates and other blood derivatives.

Authors:  Chien-Jung Huang; Yi-Chen Sun; Karen Christopher; Amy Shih-I Pai; Chia-Ju Lu; Fung-Rong Hu; Szu-Yuan Lin; Wei-Li Chen
Journal:  PLoS One       Date:  2017-02-02       Impact factor: 3.240

3.  Association of Alpha Tocopherol and Ag Sulfadiazine Chitosan Oleate Nanocarriers in Bioactive Dressings Supporting Platelet Lysate Application to Skin Wounds.

Authors:  Maria Cristina Bonferoni; Giuseppina Sandri; Silvia Rossi; Eleonora Dellera; Alessandro Invernizzi; Cinzia Boselli; Antonia Icaro Cornaglia; Claudia Del Fante; Cesare Perotti; Barbara Vigani; Federica Riva; Carla Caramella; Franca Ferrari
Journal:  Mar Drugs       Date:  2018-02-09       Impact factor: 5.118

Review 4.  Stimuli-Responsive Materials for Tissue Engineering and Drug Delivery.

Authors:  Sofia Municoy; María I Álvarez Echazú; Pablo E Antezana; Juan M Galdopórpora; Christian Olivetti; Andrea M Mebert; María L Foglia; María V Tuttolomondo; Gisela S Alvarez; John G Hardy; Martin F Desimone
Journal:  Int J Mol Sci       Date:  2020-07-02       Impact factor: 5.923

5.  Risks in Induction of Platelet Aggregation and Enhanced Blood Clot Formation in Platelet Lysate Therapy: A Pilot Study.

Authors:  Ying-Hao Wen; Chen-Fang Lee; Yu-Ju Chen; Gwo-Jyh Chang; Kowit-Yu Chong
Journal:  J Clin Med       Date:  2022-07-08       Impact factor: 4.964

6.  The corneal epitheliotrophic abilities of lyophilized powder form human platelet lysates.

Authors:  Lily Wei Chen; Chien-Jung Huang; Wen-Hui Tu; Chia-Ju Lu; Yi-Chen Sun; Szu-Yuan Lin; Wei-Li Chen
Journal:  PLoS One       Date:  2018-03-16       Impact factor: 3.240

7.  Development of prednisolone-containing eye drop formulations by cyclodextrin complexation and antimicrobial, mucoadhesive biopolymer.

Authors:  Tivadar Bíró; Gabriella Horvát; Mária Budai-Szűcs; Erzsébet Csányi; Edit Urbán; Andrea Facskó; Piroska Szabó-Révész; Ildikó Csóka; Zoltán Aigner
Journal:  Drug Des Devel Ther       Date:  2018-08-15       Impact factor: 4.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.